The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research.
Many of the current biologics in the pipeline are targeting the indications, which are small-molecule dominated and have a large patient pool. This represents that in the forecast period the trend of biologics could enter several of the non-traditional biologic disease areas, which could benefit from the increased therapeutic efficacy. Furthermore, this is also providing the room to the biosimilar market to grow.
In terms of medical efficacy, therapeutic spread, and population access biopharmaceuticals have vast potential, and much of this potential is still untapped. This potential can gradually be realized as manufacturing technologies, such as microcarrier based synthesis make progress, which may lead to commercialization of more effective therapies, increased manufacturing efficacy, and reduced therapy costs. Hence, owing to such rapid growth of the biologics and biosimilar industry, the market is positively affected.
Key Market Trends Cell Therapy is Expected to Show Fastest Growth by Application, Over the Forecast Period
Microcarriers help in cost-effective cell production i.e they contribute to reducing fixed as well as variable costs during the large scale manufacturing. With technological advancements, the current scenario has changed and the significance of microcarriers in cell therapy has increased. For instance, dissolvable microcarriers are currently there in the market that is composed of cross-linked polysaccharide polymers that can be efficiently dissolved during the cell harvest step. As the microcarriers get completely dissolved, there is no need for the separation and simply, the downstream process goes well. Therefore, these microcarriers are considered as beneficial beads for large scale cell production or cell therapy application.
Along with the above-mentioned statements, another factor that is responsible for the growth of cell therapy applications of microcarriers is that companies are currently focusing on the provision of microcarriers that contribute to the large scale and cost-effective production. For example Corning Incorporated provides dissolvable microcarriers. These factors boost the growth in cell therapy applications.
North America is Expected to Dominate the Market Over the Forecast Period
North America region is believed to have the largest share in the microcarrier market. This is majorly due to the rising gene and cell therapy research in the region along with the associations that are supporting this research. For instance, the American Society of Gene and Cell Therapy is responsible for the funding of the research and also, this society is forcing the biopharmaceutical and biotech companies to improve their R&D.
Along with that, the United States is witnessing high and rapid growth in the biologics and biosimilar Industry which is one of the major factors driving the microcarrier market in this region.
Competitive Landscape The Microcarrier market is mostly inclusive of the global players and few companies that are currently dominating the market include Thermo Fisher Scientific, Sartorius AG, Eppendorf AG, Danaher Corporation (Pall Corporation), and GE Healthcare. The competition in the market is expected to increase as new companies are also coming up in the market.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
243 pages •
By Asia Market Information & Development Company
• May 2022
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
The biopharmaceutical tubing market is expected to reach US$ 6,013.27 million by 2028 from US$ 3,442.82 million in 2021; it is estimated to grow at a CAGR of 8.3% from 2021 to 2028. The factors increasing elderly population in world, and rising demand for minimally invasive procedures are contributing to the market growth. However,...
400 pages •
By The Business Research Company
• Mar 2022
Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. The global interleukin inhibitors market is expected to grow from $26.95 billion in 2021 to $31.73 billion in 2022 at a compound annual growth...
222 pages •
By The Business Research Company
• Feb 2022
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market as it emerges from the COVID 19 shut down. Description: Where...
Executive Summary According to the report, the global Biologics CDMO Market was valued at USD 9.9 Billion in the year 2020. Growth opportunities for the Biologics CDMO market is attributed to the growth of the geriatric population, rising technical advancements by the CDMO service providers, increasing trend of outsourcing...
175 pages •
By The Business Research Company
• Feb 2022
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc, New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton,...
The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is estimated to grow at a CAGR of 10.3% from 2021 to 2028. Several factors such as the increasing prevalence of chronic diseases, rising demand for precision medicine, and the growing funding for pharmacogenomic research activities...
State of the Biopharmaceutical Industry 2022 Summary As industries emerge from the impact of COVID-19, 2022 will be a year of readjustments and transition for many businesses worldwide. While the ongoing COVID-19 pandemic continues to restrain economic recovery, pharmaceutical companies will continue...
The global next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028. Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth....
The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The market growth is attributed to factors such as the increasing prevalence...
Hormone
Biopharmaceutical
Infectious Disease
World
APAC
Diabetes Prevalence
Fertility Rate
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.